Drug Profile

Research programme: autologous induced pluripotent stem cell based therapy - Matricelf

Alternative Names: Autologous iPSC-derived therapy - Matricelf

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Preclinical Spinal cord disorders
Research Age-related macular degeneration; Myocardial infarction; Parkinson's disease

11 Mar 2025 Cellino and Matricelf collaborates to develop autologous iPSC therapy for spinal cord injury
11 Mar 2025 Early research in Age-related macular degeneration in Israel (Parenteral) prior to March 2025
11 Mar 2025 Early research in Myocardial infarction in Israel (Parenteral) prior to March 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com